ProteoGenix names Robert M. Di Tullio, Vice President, Regulatory Affairs and Quality

COSTA MESA, CA, July 21, 2008---ProteoGenix announced today that it has named Robert M. DiTullio, Vice President, Regulatory Affairs and Quality.

Mr. Di Tullio brings more than 30 years experience in the in vitro diagnostics industry. Prior to joining ProteoGenix he was Vice President, Regulatory Affairs, Quality and Clinical Affairs at Sequenom. Previously, he was Vice President, Global Regulatory Affairs at Siemens Medical Solutions Diagnostics. He joined Siemens following that company’s acquisition of Diagnostic Products Corporation (DPC), where he served as Corporate Officer and Vice President, Regulatory Affairs, Clinical and Quality Systems. Mr. Di Tullio joined DPC from his prior employment at Cirrus Diagnostics, when DPC acquired Cirrus in 1992. He previously held regulatory and quality leadership positions with Pharmacia and Behring. Robert is currently the co-chair of the AdvaMed Diagnostics Task Force, was an advisory board member for the Medical Device graduate degree curriculum at the University of Southern California for several years and has numerous professional regulatory affairs society affiliations. He received a B.S. in Biology from Saint Joseph’s University in Philadelphia.